Call Today216.600.0114
Spangenberg Shibley & Liber, LLP | Apr 8, 2009

Raptiva® (efalizumab) Psoriasis Drug Side Effects Prompts Recall

Categories: News
Cleveland, Ohio - April 8, 2009 -- Genentech announces psoriasis drug recall - Raptiva® (efalizumab) is prescribed for chronic plaque psoriasis treatment. It has been stated that approximately 46,000 patients worldwide have been treated with Raptiva since FDA approval in 2003.